Chimpanzee adenovirus vaccine provides multispecies protection against Rift Valley fever
Review statusPeer Review
MetadataShow full item record
Warimwe, G.M., Gesharisha, J., Carr, B.V., Otieno, S., Otingah, K., Wright, D., Charleston, B., Okoth, E., Elena, L.-G., Lorenzo, G., Ayman, E.B., Alharbi, N.K., Al-dubaib, M.A., Brun, A., Gilbert, S.C., Nene, V. and Hill, A.V.S. 2016. Chimpanzee adenovirus vaccine provides multispecies protection against Rift Valley fever. Scientific Reports 6: 20617.
Permanent link to cite or share this item: http://hdl.handle.net/10568/71057
Rift Valley Fever virus (RVFV) causes recurrent outbreaks of acute life-threatening human and livestock illness in Africa and the Arabian Peninsula. No licensed vaccines are currently available for humans and those widely used in livestock have major safety concerns. A ‘One Health’ vaccine development approach, in which the same vaccine is co-developed for multiple susceptible species, is an attractive strategy for RVFV. Here, we utilized a replication-deficient chimpanzee adenovirus vaccine platform with an established human and livestock safety profile, ChAdOx1, to develop a vaccine for use against RVFV in both livestock and humans. We show that single-dose immunization with ChAdOx1-GnGc vaccine, encoding RVFV envelope glycoproteins, elicits high-titre RVFV-neutralizing antibody and provides solid protection against RVFV challenge in the most susceptible natural target species of the virus-sheep, goats and cattle. In addition we demonstrate induction of RVFV-neutralizing antibody by ChAdOx1-GnGc vaccination in dromedary camels, further illustrating the potency of replication-deficient chimpanzee adenovirus vaccine platforms. Thus, ChAdOx1-GnGc warrants evaluation in human clinical trials and could potentially address the unmet human and livestock vaccine needs.